Drug Profile
GL 23X
Alternative Names: GL-23XLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Genisphere
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA
- 04 Sep 2019 Preclinical trials in Pancreatic cancer in USA (unspecified route) (Genisphere pipeline,
- 27 Aug 2019 Genisphere and University Hospitals Cleveland Medical Center entered into a agreement to study and develop unique strategies to treat pancreatic cancer